PMID- 15746850
OWN - NLM
STAT- MEDLINE
DCOM- 20050414
LR  - 20220408
IS  - 0194-5998 (Print)
IS  - 0194-5998 (Linking)
VI  - 132
IP  - 3
DP  - 2005 Mar
TI  - Overexpression of MMP-2 in laryngeal squamous cell carcinoma: a potential 
      indicator for poor prognosis.
PG  - 395-400
AB  - OBJECTIVES: To investigate the expression and clinical significance of 
      gelatinases (MMP-2 and MMP-9) in patients with laryngeal squamous cell carcinoma 
      (LSCC). STUDY DESIGN AND SETTING: In a retrospective study of 72 consecutive 
      patients with LSCC hospitalized in a single cancer center, immunohistochemistry 
      was used to examine the expression of MMP-2 and MMP-9 in surgical samples. The 
      results were compared to clinicopathological features and prognosis. RESULTS: The 
      positive expression of MMP-2 and MMP-9 in patients with LSCC was 50% (36/72) and 
      73.6% (53/72), respectively. According to the expression scale, there were 36 
      patients of -, 26 patients of +, 7 patients of ++, and 3 patients of +++ 
      expression of MMP-2; 19 patients of -, 26 patients of +, 16 patients of ++, and 
      11 patients of +++ expression of MMP-9. There was no significant relationship 
      found between the expression of MMP-2 or MMP-9 and clinicopathological features 
      of LSCC, such as histological grade, primary site, T stage, N stage, and clinical 
      stage. The 5-year overall survival (OS) and disease-free survival (DFS) rate 
      calculated by Kaplan-Meier method in patients with negative and positive 
      expression of MMP-9 and MMP-2 was 73.68%, 50.94%, 73.68%, and 49.06% in MMP-9 and 
      72.22%, 41.67%, 72.22%, and 38.89% in MMP-2, respectively. Significant 5-year 
      survival difference was found between patients with negative and positive 
      expression of MMP-2 (log rank = 6.74, P = 0.0094). There was significant lower 
      survival rate in patients with higher positive expression of MMP-2 (log rank = 
      11.77, P = 0.0028). In glottic laryngeal cancer, positive expression of MMP-2 
      could predict poor survival and was more likely to present primary recurrence. 
      CONCLUSION: The expression of MMP-2 could be used as a potential predictor for 
      poor prognosis in patients with LSCC.
FAU - Liu, Wei-Wei
AU  - Liu WW
AD  - Department of Combined Therapy No. 3, Cancer Center of Zhong Shan University, 
      Guang Dong Province, Peoples Republic of China. liuwei_2@163.net
FAU - Zeng, Zong-Yuan
AU  - Zeng ZY
FAU - Wu, Qiu-Liang
AU  - Wu QL
FAU - Hou, Jing-Hui
AU  - Hou JH
FAU - Chen, Yi-Yong
AU  - Chen YY
LA  - eng
PT  - Journal Article
PL  - England
TA  - Otolaryngol Head Neck Surg
JT  - Otolaryngology--head and neck surgery : official journal of American Academy of 
      Otolaryngology-Head and Neck Surgery
JID - 8508176
RN  - 0 (Biomarkers, Tumor)
RN  - EC 3.4.24.24 (Matrix Metalloproteinase 2)
RN  - EC 3.4.24.35 (Matrix Metalloproteinase 9)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers, Tumor/*biosynthesis
MH  - Carcinoma, Squamous Cell/genetics/*metabolism/mortality
MH  - Female
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Laryngeal Neoplasms/genetics/*metabolism/mortality
MH  - Male
MH  - Matrix Metalloproteinase 2/*biosynthesis
MH  - Matrix Metalloproteinase 9/*biosynthesis
MH  - Middle Aged
MH  - Prognosis
MH  - Retrospective Studies
MH  - Survival Rate
EDAT- 2005/03/05 09:00
MHDA- 2005/04/15 09:00
CRDT- 2005/03/05 09:00
PHST- 2005/03/05 09:00 [pubmed]
PHST- 2005/04/15 09:00 [medline]
PHST- 2005/03/05 09:00 [entrez]
AID - S0194599804018339 [pii]
AID - 10.1016/j.otohns.2004.09.050 [doi]
PST - ppublish
SO  - Otolaryngol Head Neck Surg. 2005 Mar;132(3):395-400. doi: 
      10.1016/j.otohns.2004.09.050.